Hasil Pencarian - Lugui Qiu

Perbaiki Hasil
  1. 1
    Immunotherapy for multiple myeloma: new chances and hope

    Immunotherapy for multiple myeloma: new chances and hope oleh Jingyu Xu, Gang An, Lugui Qiu

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Passion for moments and compassion for patients: in memory of Dr. Jianfeng Zhou (1966–2022)

    Passion for moments and compassion for patients: in memory of Dr. Jianfeng Zhou (1966–2022) oleh Lugui Qiu, Weiping Yuan, Gang Huang, Liang Huang

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING

    P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING oleh Jian Cui, Wenqiang Yan, Jingyu Xu, Lugui Qiu, Gang An

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P803: CRIP1 INDUCES PIS RESISTANCE BY FORMING A COMPLEX WITH USP7/PA200 AND ENHANCING PROTEASOME ACTIVITY AND AUTOPHAGY IN MULTIPLE MYELOMA

    P803: CRIP1 INDUCES PIS RESISTANCE BY FORMING A COMPLEX WITH USP7/PA200 AND ENHANCING PROTEASOME ACTIVITY AND AUTOPHAGY IN MULTIPLE MYELOMA oleh Zhen Yu, Peixia Tang, Zhenshu Xu, Lugui Qiu, Mu Hao

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P818: DNP73 PROMOTES DRUG RESISTANCE AND IMMUNE EVASION IN MULTIPLE MYELOMA BY MODULATING MYC/CD47 AXIS

    P818: DNP73 PROMOTES DRUG RESISTANCE AND IMMUNE EVASION IN MULTIPLE MYELOMA BY MODULATING MYC/CD47 AXIS oleh Lanting Liu, Jie Xu, Lixin Gong, Xiyue Sun, Lugui Qiu, Mu Hao

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P806: TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING

    P806: TRACKING THE CLONAL EVOLUTION AND DRUG RESISTANCE PATHWAY OF NEWLY DIAGNOSED MULTIPLE MYELOMA THROUGH SINGLE-CELL RNA SEQUENCING oleh Jian Cui, Shuhui Deng, Xiaoyun LI, Wenqiang Yan, Xin Gao, Lugui Qiu, Gang An

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA

    P935: EARLY RELAPSE WITHIN 18 MONTHS (ER18) IS A POWERFUL DYNAMIC PREDICTOR FOR PROGNOSIS AND COULD REVISE STATIC RISK DISTRIBUTION IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOM... oleh Wenqiang Yan, Jian Cui, Jingyu Xu, Huishou Fan, Yan Xu, Lugui Qiu, Gang An

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

    Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era oleh Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu, Kenneth C. Anderson

    Diterbitkan 2017-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    The association of HLA-C alleles with multiple myeloma in Chinese patients

    The association of HLA-C alleles with multiple myeloma in Chinese patients oleh Xiaojing Wang, Gang An, Jiying Wang, Yan Zhang, Qinghua Li, Hui wei, Lugui Qiu, Kun Ru

    Diterbitkan 2018-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2

    P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNE... oleh Xavier Leleu, Shinsuke Iida, C. Ola Landgren, Alexander Lesokhin, Eric Leip, Arthur Kudla, Gregory Finn, Lugui Qiu

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β-Catenin Nuclear Enrichment

    Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β-Catenin Nucle... oleh Zhenqing Xie, Zhenqing Xie, Yan Xu, Xiaojing Wei, Xiaojing Wei, Gang An, Mu Hao, Zhen Yu, Lugui Qiu

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value

    Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prog... oleh Gang An, Yan Xu, Lihui Shi, Zhong Shizhen, Shuhui Deng, Zhenqing Xie, Weiwei Sui, Fenghuang Zhan, Lugui Qiu

    Diterbitkan 2014-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

    Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study oleh Huishou Fan, Weida Wang, Ya Zhang, Jianxiang Wang, Tao Cheng, Lugui Qiu, Xin Wang, Zhongjun Xia, Gang An

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.

    Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. oleh Manujendra N Saha, Hua Jiang, Yijun Yang, Xiaoyun Zhu, Xiaoming Wang, Aaron D Schimmer, Lugui Qiu, Hong Chang

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways

    DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways oleh Lanting Liu, Lanting Liu, Dasen Gong, Dasen Gong, Hao Sun, Hao Sun, Fangshuo Feng, Fangshuo Feng, Jie Xu, Xiyue Sun, Xiyue Sun, Lixin Gong, Lixin Gong, Zhen Yu, Zhen Yu, Teng Fang, Teng Fang, Yan Xu, Yan Xu, Rui Lyu, Rui Lyu, Tingyu Wang, Tingyu Wang, Wentian Wang, Wentian Wang, Wenzhi Tian, Lugui Qiu, Lugui Qiu, Lugui Qiu, Gang An, Gang An, Mu Hao, Mu Hao

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    P810: A NOVEL INDIRUBIN-3-MONOXIME DERIVATIVES FUNCTION AS DISRUPTORS OF PROTEOSTASIS VIA TARGETING TRIM28 IN MULTIPLE MYELOMA

    P810: A NOVEL INDIRUBIN-3-MONOXIME DERIVATIVES FUNCTION AS DISRUPTORS OF PROTEOSTASIS VIA TARGETING TRIM28 IN MULTIPLE MYELOMA oleh Teng Fang, Hao Sun, Xiyue Sun, Lixin Gong, Peixia Tang, Zhen Yu, Lanting Liu, Shiyi Xie, Mu Hao, Lugui Qiu

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large Bcell lymphomas and regulates the pro-tumor microenvironment

    Lymphoma cell-driven IL-16 is expressed in activated B-cell-like diffuse large Bcell lymphomas and regulates the pro-tumor microenvironment oleh Xuwen Guan, Yi Wang, Teng Fang, Jingya Wang, Ru Li, Mu Hao, Lugui Qiu, CAMS Innovation Fund for Medical Sciences (CIFMS)

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

    Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma oleh Yun Leng, Lugui Qiu, Jian Hou, Yaozhong Zhao, Xuejun Zhang, Shifang Yang, Hao Xi, Zhongxia Huang, Ling Pan, Wenming Chen

    Diterbitkan 2016-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

    Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies oleh Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu, Lingyan Ping, Zongliang Liu, Hanying Bao, Zusheng Xu, Lugui Qiu

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma

    Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma oleh Junqiang Lv, Junqiang Lv, Hao Sun, Lixin Gong, Xiaojing Wei, Yi He, Zhen Yu, Zhen Yu, Lanting Liu, Lanting Liu, Shuhua Yi, Shuhua Yi, Weiwei Sui, Yan Xu, Yan Xu, Shuhui Deng, Gang An, Gang An, Zhi Yao, Lugui Qiu, Lugui Qiu, Mu Hao, Mu Hao

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: